Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content


CDC Meaningful Use Banner

NHSN Meaningful Use Overview

Declaration of Readiness for Public Health Reporting

For 2018, NHSN Antimicrobial Use (AU) and Antimicrobial Resistance (AR) (AUR) reporting have been identified as a new option for public health registry reporting under Meaningful Use Stage 3 (MU3).


See certification criterion (§ 170.315(f)(6)).

Beginning January 1st, 2017, a facility enrolled in the National Healthcare Safety Network (NHSN) will be able to register their intent to satisfy the AUR-MU3 objective. The NHSN user interface will include an AUR-MU3 registration page and allow the NHSN Facility Administrator to register AUR-MU3 intent. Active engagement for this MU3 objective includes monthly electronic reporting for a full calendar year of R1 Normative Antimicrobial Use Summary, Antimicrobial Resistance Event, and Antimicrobial Resistance Summary data in the format of Clinical Document Architecture (CDA) to NHSN.

In order to qualify as certified technology an EHR or EHR Module must be capable of creating a Clinical Document Architecture (CDA) documents for Antimicrobial Use and Resistance conformant to the HL7 Implementation Guide for CDA ® Release 2—Level 3: Healthcare Associated Infection Reports, Release 1—US Realm—August 2013. See The following CDAs must all be successfully generated.

  • Antimicrobial Resistance Option (ARO) Report (Numerator) specific document template in Section (pages 69-72);
  • Antimicrobial Resistance Option (ARO) Summary Report (Denominator) specific document template in Section (pages 54-56);
  • Antimicrobial Use (AUP) Summary Report (Numerator and Denominator) specific document template in Section (pages 56-58)

Certification will consist of validating the generated CDAs against a Schematron Validator.  A test instance of the validator may be found at  Choose the Healthcare Associated Infection (HAI) Reporting (Normative R1; June 2013) to validate against.

To learn more about Meaningful Use Incentives and Certification, see

Kindly contact the NHSN customer support desk at for questions and more information. Please copy the on all such emails, for tracking and follow up, as needed.